Fate Therapeutics Earning Date (FATE)

USA |NASDAQ |USD

FATE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 2, 2022 Jun 2022 - - $-0.58
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 2, 2022 Jun 2022 - - $13.41M

Fate Therapeutics's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 2022.

FATE Earnings Date & History Chart

FATE Earnings & Revenue Forecast

FATE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 20 $-2.84 $-3.35 $-1.96

FATE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-2.80 $-2.64 $-2.65

FATE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 20 $39.88M $0.00 $88.00M

FATE Earnings Date & Revenue History

FATE Earnings History

|
Show More
Show More

FATE Revenue History

|
Show More
Show More

Fate Therapeutics Next Earnings Date & Report

FATE Next Earnings Date & Report Preview: Jun 2022 (FQ)

FATE's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 30, 2022.

Fate Therapeutics Previous Earnings Dates & Reports

FATE Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Fate Therapeutics's previous earnings date was May 3, 2022 for its fiscal quarter ended Mar 31, 2022.

FATE Previous Earnings Date & Report Recap: Dec 2021 (FY)

Fate Therapeutics's previous annual earnings date was Feb 28, 2022 for its fiscal year ended Dec 31, 2021.

FATE's earnings per share (EPS) was $-2.19, beating the consensus analysts forecast of $-2.21 by -0.90% , and lower than the previous year's EPS (Dec 2020) by 5.29%.

Revenues were $55.85M, better than the forecast of $49.96M by 11.78%, and up by 77.66% from previous year's revenue.

The company reported a net income of $-212.15M.

Fate Therapeutics reported a free cash flow of $-213.57M for its fiscal year, compared to $-44.16M a year ago.

The company ended the fiscal year with $114.82M in total debt, an increase of 18.01% compared to the previous year.